|Articles|May 5, 2014

European Pharma Launches Strategy Manifesto

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

The manifesto is built on three “separate but highly interdependent pillars”:

1. Improve health outcomes & remove inequalities to better patient benefits;
2. Support sustainable & predictable healthcare systems to speed access to medicines;
3. Build a thriving innovative life sciences sector to promote European competitiveness. 

It follows the launch of EFPIA’s #HealthyEU Health and Growth campaign, which outlines opportunities and threats faced by the patients and the healthcare sector.

EFPIA President, Sanofi CEO Christopher Viehbacher, highlighted how the technological, behavioural and therapeutic innovations outlined in the Manifesto should be used to rebuild sustainable healthcare systems, improve access to medicines and “do a better job at preventing and treating chronic disease”.

The  research-based pharmaceutical industry employs over 700,000 people in Europe, and contributes  17% of total business enterprise R&D employment.

To view the EFPIA Maifesto, click here.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.